Pharmaceutical Non-Active Ingredients TRIZ Cases
- Thermothickening Colloid Composition for Stable High-Temperature Viscosity
Two associating polymers with different solubilities create a self-stabilized fluid that thickens with heat without added surfactants.
- CD47-Binding Therapeutic Conjugates for RBC-Mediated API Delivery
CD47-binding conjugates hitchhike on red blood cells, then transfer into target cells by endocytosis to block immune escape and deliver APIs.
- CAR-Engineered Neutrophil Vesicles for Glioblastoma BBB Delivery
Engineered neutrophil vesicles carry CAR and miRNAs across the blood-brain barrier to suppress GBM while reducing toxicity and T-cell exhaustion.
- Fast-Disintegrating Tablet With Liquid Crystal Controlled Release
An amphiphilic ODT disintegrates quickly in saliva, then forms liquid crystalline particles to slow release and improve bioavailability.
- SST2R Non-Peptide Drug Conjugates for Selective Tumor Targeting
Selective SST2R-targeted non-peptide conjugates deliver cytotoxic payloads to tumor cells while reducing harm to healthy tissue.
- Hydrolytically Degradable Zwitterionic Polymers for Anti-Fouling Drug Delivery
A degradable polyphosphazene with HEPES-based zwitterionic groups resists protein binding while avoiding PEG-related immunogenicity.
- Porous Annulus Contact Lens for Biologic Delivery and Optical Clarity
A clear central zone with a porous annulus enables sustained biologic release from a contact lens without sacrificing optical clarity.
- Aqueous Enteric Capsule Films Without Solvents or Thermal Stress
A low-viscosity alginate and HPMC aqueous film forms GRAS capsule shells with delayed release, avoiding solvents and thermal shaping.
- Tumor-Targeting NIR Dye-Drug Conjugates for Selective Chemotherapy
A cleavable NIR dye-drug conjugate targets tumors, releases chemotherapy locally, and reduces off-target toxicity while enabling imaging.
- PEG Aldehyde Synthesis via Acetal Intermediates for High Purity
A cyclic acetal route avoids PEG chain decomposition and unstable precursors, delivering high-purity PEG aldehydes without column chromatography.
- PSMA-Targeted LPEI-PEG Polyplexes With Defined PEG Conjugation
Chemoselective PEG linking creates homogeneous PSMA-targeted LPEI polyplexes that reduce aggregation and improve selective nucleic acid delivery.
- Antibody-Drug Conjugate Linker Design for Defined DAR Control
Site-specific cysteine and lysine conjugation with enzyme-sensitive linkers improves DAR uniformity, payload control, and ADC safety.
- Cell-Wall-Broken Herbal Granules With Uniform Particle Size
A staged wall-breaking, screening, and ethanol-water pelletizing process improves particle uniformity, stability, and dissolution of herbal granules.
- Natural Additive Composition for Stable Particle Pores in Tablets
Jujube-based additives stabilize particle pores to improve tablet fluidity, hardness, disintegration, and weight uniformity without synthetic aids.
- AZD4635 Pellet Coating Formulation for Oral Bioavailability
Coated cellulose pellets with PVP and dual surfactants improve AZD4635 solubility, dosing convenience, and oral exposure.
- Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
A biweekly liposomal irinotecan, oxaliplatin, and 5-fluorouracil regimen improves tumor control with lower toxicity than FOLFIRINOX.
- Polyether Bioconjugates That Avoid Anti-PEG Immune Response
Side-chain polyether polymers replace PEG to reduce anti-PEG antibody binding, crystallization, and dispersity in bioconjugates.
- STING PROTAC Compounds for Targeted Degradation in Constitutive Activation
PROTAC compounds recruit E3 ligase to degrade STING, suppressing constitutive activation with lower exposure and fewer off-target effects.
- Thermosensitive Prodrug Hydrogel for Sustained Joint Drug Delivery
A thermoresponsive polymer-drug gel forms a local joint depot to extend arthritis relief while reducing repeat injections and systemic exposure.
- Controlled-Release PGI2 Agonist Composition for Once-Daily PAH Dosing
Controlled-release Compound 1 formulations balance plasma levels for once-daily oral PAH treatment while reducing side effects.
- Metal-Bound Ionic Composition for Multi-Pathway Cancer Metabolism Disruption
Combining two cancer-metabolism agents with a metal ion disrupts glycolysis and calcium homeostasis to suppress proliferation and metastasis.
- Migalastat Pregnancy Dosing for Fabry Disease Treatment
Alternate-day migalastat dosing treats Fabry disease during pregnancy while limiting fetal exposure and supporting normal birth outcomes.
- 3-Amino-5-Phenylbenzamide EZH2 PROTACs for Low-Dose Degradation
By converting covalent EZH2 inhibitors into PROTACs, this case achieves low-dose EZH2 degradation and stronger suppression of cancer cell growth.
- FN3-siRNA Conjugates for Muscle Glycogen Reduction
CD71-targeted FN3-siRNA conjugates improve skeletal muscle delivery, reduce glycogen buildup, and support biomarker-based dosing in Pompe disease.
- Aryl-Quinolin Linker-Payload for Targeted Antibody Drug Delivery
An aryl-quinolin linker-payload enables antibody-guided cancer drug delivery, raising tumor exposure while limiting non-specific toxicity.
- Bifunctional Small Molecules for Selective Circulating Protein Degradation
Linked small molecules recruit circulating proteins to hepatocyte receptors for degradation, reducing protein levels without antibody weight and cost.
- Adhering Antacid Lozenge for Fast Dissolution and Local Acid Neutralization
A two-layer adhering lozenge uses soluble binders to release calcium carbonate quickly in the mouth and throat while limiting stomach neutralization.
- Method for producing low-substituted hydroxypropyl cellulose
A screw press sets L-HPC moisture to 50-60% to improve tablet disintegratability while maintaining compactibility.